Telegram RegisterThe public register of Telegram
Telegram profile photo for [신한 리서치본부] 제약/바이오

Channel

[신한 리서치본부] 제약/바이오

@bio_shinhan

On this record: Topic · Observations · Also posting the same content · Growth · Engagement · What this channel posts · Posts · Posts edited after publishing · Citations · Cite this entry

21,437subscribers

+195 since we began measuring on 6 August 2026

Risers and fallers across the register · movement among entries of 10,000–31,623.

Register entry

Telegram ID-1001604473784
TypeChannel
Username@bio_shinhan
Description안녕하세요. 신한투자증권 제약/바이오 담당 엄민용 연구위원, 이호철 수석연구원, 윤석현 연구원(RA), 임재현 연구원(RA) 입니다. 리서치본부 내 공표된 조사분석자료를 실시간으로 제공 할 수 있도록 정보 전달을 위해 운영되는 채널입니다.
CreatedBetween 1 December 2021 and 30 April 2023 — estimated from Telegram’s id allocation, not measured. How this range is calculated.
First recorded6 August 2026
Last confirmed live17 September 2026
Measurements held30
Confirmed unchanged1 time, most recently 17 September 2026
On Telegramt.me/bio_shinhan

Topic

Other / unclassifiable — a classification, not a measurement. An on-box language model (Qwen3.6-35B-A3B-UD-Q6_K_XL, prompt version 1) read this channel’s own recent posts on 10 August 2026 and assigned it the closest of 31 fixed categories, at 66% confidence. This is a model’s judgement about what the channel is likely to be about, not a fact this register measured the way a subscriber count or a view count is measured — it can be revised on a later pass, and it carries no weight anywhere else on this page. How this classification works, and why it has no browse page of its own yet.

Observations

These are measurements, not verdicts. Each one below states something we counted, alongside the evidence it was counted from, so you can check it rather than take it. None of them is graded: every observation this register holds is recorded at severity 0, because the precision of the detectors behind them has not been measured yet, and a rating we cannot support is worse than none. Read each as a fact about the data, not as a judgement about the channel. How we measure.

Content that also appears on other registered channels

Posts published here appear word for word on 2 other registered channels. The matching is on the text itself, not on Telegram’s forward marker, so it finds a copy whether or not it was labelled as one.

Matching posts — open both and compare (4 of the pairs behind the counts below)
Posted firstThenOverlapGap
@bio_shinhan/4664 · this entry4 Aug 2026, 11:01 UTC@SmartnGrowth/5744 Aug 2026, 11:02 UTC1.0072 seconds
@SmartnGrowth/5794 Aug 2026, 22:55 UTC@bio_shinhan/4668 · this entry4 Aug 2026, 23:46 UTC1.0050 minutes
@alteogenIR/25130 Jul 2026, 23:08 UTC@bio_shinhan/4655 · this entry30 Jul 2026, 23:31 UTC1.0023 minutes
@alteogenIR/25431 Jul 2026, 05:31 UTC@bio_shinhan/4657 · this entry2 Aug 2026, 22:49 UTC1.003 days
Every channel this entry shares post bodies with
ChannelMatching postsText overlapTypical gapPublished first
@SmartnGrowth6 (6/6 hand-verifiable sample passed)1.003 minuteseven
@alteogenIR6 (6/6 hand-verifiable sample passed)1.0037 minutes@alteogenIR (5–1)

Text overlap is the Jaccard coefficient over the set of distinct three-word phrases in the two bodies: 1.00 is identical wording, and the threshold for counting a pair at all is 0.70. Candidates are generated by simhash LSH (4 x 16-bit bands, exact Hamming <= 3) verified against the bodies with Jaccard over the SET of distinct 3-word shingles. Published first counts which side of each matching pair carries the earlier timestamp — in this corpus, which is the limitation directly below.

What this cannot establish

MEASURED, DOMINANT ERROR SOURCE: a post ingested before 2026-08-06 may have carried a forward header that was not recorded. A 45-pair hand-check against live t.me pages found 14 (31%) where the live page shows a forward header naming the other channel and the database has none, plus 4 more (9%) naming a third party. The text match itself was wrong 0 times out of 45. Read attribution_capture.items_in_trusted_window before treating the unattributed count as a claim.

Telegram lets a channel forward a post with a header naming the source, and we only began reliably recording that header on 2026-08-06. None of the 2 matches recorded here fall after that date, so for this entry we cannot say whether any of them carried a credit. The duplication is measured; the absence of attribution is not.

“Published first” means first in this corpus. We hold 21 comparable posts for this entry, running 30 July 2026 to 7 August 2026. A channel we have read one page deep will look younger than a neighbour we have read in full, and the order would flip with no change in the underlying facts.

The detector’s own notes on this observation, as it recorded them. Names in this_style are fields of the underlying evidence record, which the plain-English paragraphs above read out for this entry.

  • Verbatim republication has three causes and the text separates only two: a clone/mirror, unattributed copy-paste, or BOTH channels copying a common third source that neither attributes. The spread filter (content held by at most 8 channels) reduces the third and does not remove it.
  • 'Earliest' means earliest IN THIS CORPUS. A channel ingested one page deep will look younger than a neighbour ingested in full; corpus_coverage above is there to be checked before the direction is believed.
  • shared_verified_est extrapolates the sampled pass rate over the full narrow match count; sampled/passed are the numbers actually measured.
  • Absence of a forward header is not proof of intent: Telegram lets a channel disable forward attribution, and a credit written in the body is not parsed as attribution here (mention_edge_either_way above is the closest available signal).

Across the whole group of 3, the earliest publisher we hold is @alteogenIR. That is a statement about our reading window, not a claim of authorship.

Recorded under the keys clone_copy · clone_mutual, last confirmed 7 August 2026. An observation that a later pass no longer finds is cleared, and a cleared observation is removed from this page rather than being shown struck through — we do not keep publishing a claim we have withdrawn. Dispute an observation.

Also posting the same content

This channel’s posts match, word for word or near enough, posts on 2 other registered channels, found by comparing text fingerprints across every channel on the register. That matching has been checked by hand against the live Telegram pages and found reliable — 0 wrong of 45 pairs re-read.

Which channel, if either, published first is deliberately not shown. The same hand-check found that reading wrong 18 of 45 times — 60%, no better than a coin flip — because it depends on how deep our own crawl happened to reach into each channel’s history, not on when the content was actually first posted. This list is ordered by subscriber count, the same as every other listing on this site, never by which channel we think came first. Word-for-word matching has several ordinary explanations besides copying — a channel mirroring itself, an unattributed repost, or two channels independently repeating the same wire story — and this measurement cannot tell those apart. How this is measured.

Growth

21,22421,43721,330.56 August 2026 — 21,242 subscribers6 August 2026 — 21,241 subscribers7 August 2026 — 21,236 subscribers8 August 2026 — 21,235 subscribers9 August 2026 — 21,237 subscribers10 August 2026 — 21,246 subscribers13 August 2026 — 21,244 subscribers15 August 2026 — 21,242 subscribers17 August 2026 — 21,241 subscribers18 August 2026 — 21,234 subscribers19 August 2026 — 21,224 subscribers20 August 2026 — 21,247 subscribers21 August 2026 — 21,244 subscribers23 August 2026 — 21,304 subscribers24 August 2026 — 21,330 subscribers26 August 2026 — 21,332 subscribers26 August 2026 — 21,333 subscribers28 August 2026 — 21,332 subscribers28 August 2026 — 21,330 subscribers30 August 2026 — 21,326 subscribers1 September 2026 — 21,341 subscribers2 September 2026 — 21,334 subscribers3 September 2026 — 21,351 subscribers4 September 2026 — 21,350 subscribers7 September 2026 — 21,353 subscribers10 September 2026 — 21,338 subscribers12 September 2026 — 21,395 subscribers14 September 2026 — 21,398 subscribers15 September 2026 — 21,432 subscribers17 September 2026 — 21,437 subscribers6 August 202617 September 2026
30 measurements spanning 43 days, net +195. Dots are measurements; the straight line between them is drawn to join them, not to claim we know the path taken in between — snapshots are recorded only when a count changes, so gaps mean “no change observed”, never “interpolated”. The vertical axis spans 21,192–21,469 and does not start at zero.
Measurement log — every subscribers count we have recorded, most recent 20 of 30
Measured (UTC)SubscribersChange
17 Sept 2026, 21:3821,437+5
15 Sept 2026, 21:5521,432+34
14 Sept 2026, 08:0021,398+3
12 Sept 2026, 19:1721,395+57
10 Sept 2026, 21:5821,338-15
7 Sept 2026, 20:1621,353+3
4 Sept 2026, 23:3621,350-1
3 Sept 2026, 09:4721,351+17
2 Sept 2026, 01:2421,334-7
1 Sept 2026, 02:0821,341+15
30 Aug 2026, 01:1521,326-4
28 Aug 2026, 22:0721,330-2
28 Aug 2026, 00:4821,332-1
26 Aug 2026, 22:3321,333+1
26 Aug 2026, 00:3421,332+2
24 Aug 2026, 21:2721,330+26
23 Aug 2026, 08:2521,304+60
21 Aug 2026, 20:3421,244-3
20 Aug 2026, 19:0521,247+23
19 Aug 2026, 20:1221,224first reading

Engagement

111 posts held, back to 30 July 2026 — the reader has not yet reached the start of this channel’s public history, so older posts may sit further back, unread. Read across 59 pages of Telegram’s post history, 20 posts per page.

ERR · 30 days
33.1%
avg views ÷ 21,437 subscribers
Avg views / post
7,090
34 posts measured
Reaction rate
—
this channel exposes no reaction counts
Posts in window
34
of 111 held

ERR is average views per post over the last 30 days divided by subscribers, the definition TGStat uses, so this figure is comparable with the one you will see elsewhere. It falls structurally as a channel grows: a high ERR on a small channel and a low one on a large channel describe reach mathematics, not quality. We publish the figure and the sample it came from and pass no verdict on it.

ER is defined industry-wide as (forwards + reactions + comments) ÷ views — note the denominator is views, not subscribers. Telegram’s public web preview carries views and reactions but not forward or comment counts, so the reaction rate above is the reactions term only and is therefore a floor: the true ER for this channel is higher by an amount we have not measured and will not estimate.

What these figures were computed from
WindowRolling 30 days · latest post in window 23 September 2026
Posts held111 (30 July 2026 – 23 September 2026)
Views total240,910
Reactions total—
Forwards / commentsnot exposed by the public surface — not measured, not estimated
Readings taken27 Sept 2026, 04:42 UTC

Views are a single reading per post, taken at the time above. A post published in the last day or two is still accumulating views, which pulls the 30-day average down slightly. That is a property of the standard definition rather than a fault in it, so we keep the definition rather than “correcting” the number into something nobody can reproduce.

Precision. Telegram publishes view counts on its public widget in short form — 8.12K, 3.7M — so any reading at or above 1,000 reaches us rounded to three significant figures, and only counts below 1,000 are exact. Averages and rates derived from them are shown to the same precision rather than to the unit: a figure like 3,701,250 would assert digits nobody measured.

Reaction counts are published per emoji and rounded the same way, so a total below 1,000 is exact and a larger one is a sum that may carry a rounded component from each emoji above 1,000. Because it is a sum, it does not look rounded — read a large reaction total as three significant figures per contributing emoji rather than as the figure it prints.

What this channel posts

Photos
≈820
Links
≈3,330

Lifetime counters from Telegram’s own channel header, read 27 September 2026 — not the date at the top of this page, which is when the subscriber count was last read. A count marked ≈ was rounded by Telegram before we ever saw it — t.me prints these counters in full below 1,000 and to three significant figures above, so ≈142,000 means somewhere between 141,500 and 142,499.

Recent posts

23 Sept 2026, 12:10 UTC≈14,700 viewsread 27 September 2026

[IMVT-1402 CLE 임상 결과 코멘트] IMVT-1402는 이전에 CLE(피부 홍반성 루프스)로 소수 환자 Case study에서 600 mg → IgG -78% → CLASI-A -64%로 성공해 이번 randomized 2상 실패가 예상치 못한 결과 아제넥스도 LN(루푸스신염) 유사 적응증에서 2상 실패했던 이력이 있고, IMVT-1402가 더 강력한 IgG 감소를 일으켜 기대감이 높았는데 루프스 자체가 항FcRn 기전이 워킹하지 않는다는 케이스로 결론내려지는듯 함 이번 CLE 실패가 한올/이뮤노반트의 IMVT-1402 전체 플랫폼을 부정하는 데이터라고 보기는 아직 어렵고, 오히려 “FcRn이 어느 자가면역까지 확장 가능한가?"에서는 아제넥스와 같이 루스프 계열 실패가 동일하게 나온 정도 난치성 류마티스 관절염(D2T RA)…

23 Sept 2026, 05:51 UTC≈3,170 viewsread 27 September 2026
Forwarded from @alteogenIR

안녕하세요. 알테오젠의 ALT-B4와 MSD의 펨브롤리주맙을 결합한 피하주사 제형 관련 조성물 특허가 유럽특허청(EPO)에 등록됐습니다. 미국에 이어 유럽에서도 조성물 특허를 확보하며 키트루다 SC™의 지식재산권 보호 기반을 확대했습니다. 이번 유럽 특허의 존속기간은 2040년까지이며, 추가적 보호증명(SPC)을 통한 기간 연장도 가능합니다. 알테오젠은 물질·조성물·제조·고정용량복합제 관련 특허 포트폴리오를 지속적으로 강화해 하이브로자임 플랫폼 파트너의 안정적인 사업화를 뒷받침하겠습니다. [보도자료] https://alteogen.com/kr/sub/ir/news.php?mode=view&bid=1&idx=373&page=1

22 Sept 2026, 23:01 UTC≈4,820 viewsread 27 September 2026

✅ 2026.09.23(수) 바이오/제약 주요 뉴스 FDA, 에이비엘바이오/컴패스 담도암 치료제 '토베시미그(DLL4 x VEGF 이중항체) 허가신청 전 생존이익 입증 임상 권고…컴퍼스는 "새 임상 불필요" 기조, 이미 2/3상에서 PFS 4.7개월(HR 0.44)로 유효성 확인됐으며 담도암 환자 미충족 수요 고려 시 신규 임상 불필요 의견, 의견 조율 위한 협력 의지 시사 https://www.thebionews.net/news/articleView.html?idxno=28404 바이킹 비만 치료제 VK2735(GLP-1/GIP 이중작용제), 21주간 주 1회 투여 시 최대 19% 체중 감소 → 격주 투여 전환군 최대 감량 효과 97% 유지, 월 투여 전환군 90% 유지되며 유지요법의 높은 개연성 확인, 경구제형 유지요법 탐색 시험도 진…

22 Sept 2026, 04:13 UTC≈5,570 viewsread 27 September 2026

[단독] 알테오젠 ‘제르세팍SC’ 상용화 가시권…내년 3월 유럽 허가 전망 - 인타스, ALT-B4 적용 600mg SC 제형 유럽 허가 절차 진행 - 매출 연동 로열티 최대 두 자릿수 구간…후속 상업화 파이프라인 윤곽 알테오젠이 2021년 공개한 계약에 따르면 인타스는 제품 매출에 따라 중간 한 자릿수에서 낮은 두 자릿수 수준의 단계별 로열티를 지급한다. 제르세팍SC가 허가와 판매까지 이어질 경우 알테오젠에는 또 하나의 상업화 파이프라인이 추가된다. 네덜란드 의약품 전망 시스템 ‘호라이즌스캔’에 따르면 제르세팍 600mg SC는 지난 4월 유럽의약품청(EMA)에 허가 신청이 제출됐다. 현재 심사 중이며 예상 등록 시점은 2027년 3월로 잡혀 있다. https://markettimes.co.kr/?p=1901

22 Sept 2026, 01:57 UTC≈5,370 viewsread 27 September 2026

에이비엘바이오, 대표이사 가족까지?..."아직 조사대상 아냐" 업계 안팎에선 합동대응단의 압수수색 이후 이 대표의 가족이 의혹에 연루돼 조사를 받고 있다는 얘기가 흘러나왔으나 본지 취재 결과 이 대표의 가족은 현재 조사 대상이 아닌 것으로 확인됐다. https://naver.me/FM9yONl0

21 Sept 2026, 22:57 UTC≈4,910 viewsread 27 September 2026

✅️ 2026.09.22 (화) 바이오/제약 주요 뉴스 오스코텍, 최대주주와 2대주주 의결권 공동행사 약정으로 지분 22.25% 의결권 같은 방향으로…초다수결의제 폐지 및 고종성·김성연·박종철 등 신규 이사 3인 선임안 다루는 임시주총 청구, 기업가치 극대화 기준으로 의사결정 시사 https://www.thebionews.net/news/articleView.html?idxno=28336 삼성바이오 노조 "후속 파업 돌입할 수도"…오늘 사후조정서 추가 진전안 제시되지 않는 한 단체행동 불가피하다 언급 https://www.hankyung.com/article/202609219064i 노보의 비만/당뇨 신약 후보물질 카그리세마(카그릴린타이드 + 세마글루타이드_위고비 복합제), 당뇨 3상에서 60주차 체중감량 -12.4%(vs. 마운자로 5…

20 Sept 2026, 22:58 UTC≈5,050 viewsread 27 September 2026

✅ 2026.09.21(월) 바이오/제약 주요 뉴스 알테오젠, ALT-B4 적용 피하주사 제형 ‘키트루다’ 일본 최초 SC 면역항암제로 판매 승인 획득...기존 정맥주사 제형과 동일한 광범위한 암 적응증 확보, 글로벌 주요 시장 상업화 기반 확대 https://www.thebionews.net/news/articleView.html?idxno=28266 한미약품, 문제의 북경한미 매출채권 회수 중…주주 제안 적극 반영해 7월부터 북경한미 매출채권 관련 회수 계획·재발 방지 대책 추진, 투명하고 선진적인 내부 통제 및 관리 체계 구축할 것 https://www.medisobizanews.com/news/articleView.html?idxno=142412 에스티팜, 913억 올리고 핵산 원료의약품 수주 “역대 단일 계약 최대”…올해부터 내…

18 Sept 2026, 00:24 UTC≈4,980 viewsread 27 September 2026
Forwarded from @alteogenIR

안녕하세요, 알테오젠의 ALT-B4가 적용된 MSD의 피하주사 제형 키트루다가 일본에서 제조 및 판매 승인을 획득했습니다. 일본 제품명은 ‘키젝트(Kiject®)’로, 기존 정맥주사 제형 키트루다와 동일한 광범위한 암 적응증에 사용할 수 있습니다. 일본에서 허가된 첫 번째 피하주사 제형 면역관문억제제이기도 합니다. 기존 정맥주사 제형은 투여에 약 30분이 소요되는 반면, 피하주사 제형은 약 1~2분 만에 투여할 수 있어 환자와 의료진의 치료 부담을 줄일 것으로 기대됩니다. 이번 승인으로 ALT-B4가 적용된 키트루다 SC는 미국, 유럽, 캐나다에 이어 일본까지 주요 글로벌 시장에서 상업화 기반을 확대했습니다. 알테오젠은 앞으로도 글로벌 제약사들과 협력해 다양한 바이오의약품의 피하주사 제형 전환과 하이브로자임(Hybrozyme®) 플랫폼…

17 Sept 2026, 22:59 UTC≈11,600 viewsread 27 September 2026

『제약/바이오 - K-바이오, 뉴코가 미래다』 기업분석부 이호철, 엄민용 ☎️ 02-3772-2669 M&A 숫자로 확인되는 뉴코 트렌드 뉴코(NewCo)는 'New Company'의 줄임말로, VC 등 투자자가 소수의 신약만 개발하기 위해 세운 독립 회사를 뜻한다. 특정 신약에 리소스를 집중 투입해 임상을 빠르게 진행하고, 빅파마 M&A로 조기 Exit 가능하다는 게 특징이다. 실제 2024년 이후 대형 M&A 80건 중 29건(36%)의 피인수기업이 뉴코였다. 특히 중국 신약을 서구권 뉴코에게 L/O하고, 해당 뉴코를 빅파마에 매각함으로써 지정학적 리스크를 회피하는 전략이 각광을 받고 있다. 뉴코 열풍의 배경, 윈-윈 구조 [원개발사 관점 장점 3가지] 1) 뉴코 지분으로 이익 극대화: 항서제약은 2024년 5월 뉴코 카일레라에 신약을…

17 Sept 2026, 22:56 UTC≈5,910 viewsread 27 September 2026

✅ 2026.09.18(금) 바이오/제약 주요 뉴스 오름, BMS 기술수출 DAC ‘ORM-6151’ 개발 중단…임상 1상 데이터 검토 후 ‘개발 중단’ 결정, 오름 “DAC 플랫폼 기반 자체 파이프라인에 연구개발 집중” https://www.thebionews.net/news/articleView.html?idxno=28236 AZ/다이이찌산쿄의 유방암 치료제 엔허투(HER2 타깃 항체), 영국서 HER2-low 유방암 급여 확정, 접근성 확대로 시장 확장 순항 중 https://www.reuters.com/legal/litigation/astrazeneca-daiichi-breast-cancer-drug-cleared-nhs-use-england-2026-09-17/ 알테오젠, 초장기지속형 플랫폼 PCT 출원…‘월 1회’ 비만약 ‘A…

17 Sept 2026, 07:40 UTC≈3,560 viewsread 27 September 2026
Forwarded from @darthacking

2026.09.17 13:46:14 기업명: 에스케이바이오팜(시가총액: 6조 1,711억) A326030 보고서명: 투자판단관련주요경영사항 제목 : 파킨슨병 치료제(c-Abl/LRRK2 이중 저해제) 신약 후보물질 라이선스(Licensing-in) 계약 * 주요내용 ※ 투자유의사항 동 계약은 조건부 계약으로서, 본 계약을 통한 비용 인식은 임상시험과 품목허가 등의 성공 여부에 따라 달라질 수 있습니다. 계약 조건에 따라, 규제기관에 의한 연구·개발의 중단, 품목허가 실패 등 발생시 계약이 해지될 수 있습니다. 1) 계약상대방 : 주식회사 퍼스트바이오테라퓨틱스(한국) 2) 계약의 내용 : 파킨슨병 치료제로 개발 중인 'c-Abl/LRRK2 이중 저해제'에 대한 독점적 라이선스 취득(전세계) 3) 계약 체결일 : 2026년 09월 17…

16 Sept 2026, 22:45 UTC≈14,700 viewsread 27 September 2026

『올릭스(226950.KQ) - 신한 콥데이 - 오버행? 4Q 결과들 쏟아진다』 기업분석부 엄민용, 이호철 ☎️ 02-3772-1546 ▶️ 신한생각: 오버행 우려 해소, 이제 올라갈 일만 남았다 5가지 긍정적 요소 기대 가능. 9월 15일 1,150억원 CPS 1년 보호 예수 해제된 165.7만주가 보통주 전환 완료. 오버행이 유일한 우려였던 상태로 이제 상승세 전환 예상. 하반기 엘나일람, 애로우헤드 등 siRNA 경쟁사들이 비만 영역에서 ALK7 최초 임상 결과들 발표할 예정. 올릭스 ALK7 주목 ▶️ 남은 하반기 가장 높은 성장을 앞둔 기업, 핵심 5가지 포인트 1) 릴리 L/O했던 MASH 치료제 OLX702A 2상 진입 및 1상 결과 수령 2) 릴리와 신규 플랫폼 OASIS-Dual(이중 siRNA) MASH 추가 L/O 순…

Showing the 12 most recent of 111 posts we hold for @bio_shinhan. View and reaction counts are the latest single reading for each post, not a live figure, and a recent post is still accumulating both. A view count marked ≈ was rounded by Telegram before we ever saw it — t.me prints views in full below 1,000 and to three significant figures above, so ≈1,200,000 means somewhere between 1,150,000 and 1,249,999. Unmarked counts are exact. Text is reproduced from the public post preview and truncated for length.

Posts edited after publishing

@bio_shinhan edited 3 posts after it first published — the same permalink now carries different wording than the one this register originally read, caught because our own crawl held a copy of the earlier text.

An edit is not deception. Typo fixes, price updates and corrections look exactly like this too — this register can tell you the wording changed and when, not why. How this is measured.

First edit seen
13 August 2026
Most recent edit
28 August 2026

Forward network

Republished by

Channels on the register that have forwarded this channel's posts into their own feed.

Yeouido Lab_여의도 톺아보기
@Yeouido_Lab · 43,309
8 posts
팔칠사공스토너 실전투자 인사이트
@stoner8740 · 11,012
7 posts
돼지바
@bbong_tta · 12,692
4 posts
인상주의 투자 인생 업그레이드노트
@insangnism · 11,308
4 posts
텐렙
@Ten_level · 17,116
3 posts
🗽엄브렐라(Umbrella Research) 리서치+ 네프콘 옆집부자형 since 2020
@umbrellaresearch · 12,831
3 posts
조기주식회 공부방
@EarlyStock1 · 24,432
2 posts
지아이이노베이션 공식 IR
@GIInnovation · 2,082
2 posts
현업자의 맘대로 겜투일지
@Game2diarychannel · 553
2 posts
알테오젠 IR
@alteogenIR · 9,790
2 posts
제약/바이오/미용 원리버 Oneriver
@pharmbiohana · 29,812
2 posts
LSKP CFO의 개인 공간❤️
@valuecore · 1,090
2 posts
MJ의 Bio & Healthcare
@BarbarianBHC · 4,933
1 post
오를주식 - 뉴스/경제/주식
@GoUpstock · 20,978
1 post
[IV Research]
@IVResearch · 2,473
1 post
MYCloud Partners
@MycloudPartners · 1,030
1 post
스마트앤그로스 (Smart & Growth)
@SmartnGrowth · 3,309
1 post
상장기업 수사대 ☎️
@cyber_rangers · 16,973
1 post
간절한 투자스터디카페
@desperatestudycafe · 18,824
1 post
이프로 밸류스탁
@epro_valuestock · 305
1 post
빠르고 정확한 주식정보방
@fastest_info1 · 13,317
1 post
호그니엘
@hogniel · 15,315
1 post
아이엠바이오로직스 IR/PR
@imbiologics_official · 519
1 post
김찰저의 관심과 생각 저장소
@kimcharger · 24,877
1 post
投資, 아레테
@mstaryun · 18,661
1 post
너쟁이의 성실한 추추생활
@nje2e · 8,478
1 post
힙한 펭미업의 1인칭 시점
@pengmeup · 9,129
1 post
큐리언트 스토리
@qurient · 1,460
1 post
서초동 투자머신
@twomachine · 5,303
1 post

Built only from forwarded posts we have actually read, on both sides. Coverage is early and deliberately incomplete: a missing link means we have not read the post that would prove it, never that the relationship does not exist. Counts are distinct forwarded posts observed, so they only ever go up as we read more.

Mentions

Named by 3 registered channels — every channel on the register whose own posts have named this one, by its current username or any other username it currently holds, merged from two separately captured readings of the same fact so a namer caught by only one of them is not missed and a namer both caught is not counted twice. A username this channel has since dropped is not matched — that handle may belong to someone else now, and crediting today’s namer to yesterday’s owner would misattribute it.

Names

Channels on the register whose handles appear in this channel's posts.

A mention is a weaker signal than a forward and is counted separately for that reason — naming a channel is not republishing it, and a handle in a post body is easy to place deliberately. The post counts beside each row below are distinct posts in which the handle appeared, from posts we have read on both sides — the “Named by N registered channels” figure above is a different count, of distinct NAMING CHANNELS rather than posts, and is not the sum of the rows under it.

Cite this entry

A live page changes as we take new readings, so a citation should name the measurement it is based on, not just the URL. The line below cites the subscriber count as measured 17 September 2026 — this entry's latest reading, not the date you are reading this.

“[신한 리서치본부] 제약/바이오” (@bio_shinhan), 21,437 subscribers as measured 17 September 2026. Telegram Register, tgregister.com/channel/bio_shinhan.

Full measurement history, CC BY 4.0. Every reading this register holds for this entry, not just the latest one, as a dated, downloadable record: CSV · JSON. Free to use with attribution to tgregister.com. Each file carries its own generation timestamp, which is the figure to cite for exactly when the data was retrieved.